|
|
| Scientific Advisory Board |
 |
 |
|
Associate Prof. Susan Clark, Sydney Cancer Centre,
Sydney, Australia
Prof.Dr.med. Manfred Dietel, Charité,
Berlin, Germany
Dr. Peter Jones, USC Norris Cancer Center,
Los Angeles, California
Dr. Peter Laird, USC Norris Cancer Center,
Los Angeles, California
Scientific Consultants and Co-founders:
Dr. Ivo Gut
Head of Technology Development, Centre National de Génotypage, Paris, France
Expertise: mass spectometry
Prof. Jörn Walter
Head of Genetics Department, Universität des Saarlandes, Saarbrücken, Germany
Expertise: DNA methylation |
|
|
|
|
|
Dr. Susan Clark, Sydney Cancer Center
Dr. Susan Clark gained her PhD in biochemistry in 1982 at Adelaide University, Australia, after which she worked in the biotechnology industry for 10 years developing genetically engineered products such as animal vaccines and human pharmaceuticals. A decade ago she went back to basic research studying gene regulation, in particular the role of DNA methylation in development and in cancer. The lab\'s major breakthrough came with the development of a new technique (bisulphite sequencing) to analyse methylation patterns of individual cytosines. Dr Clark\'s major focus is now on the role of methylation during cancer. In collaboration with scientists from CSIRO, Dr Clark\'s groundbreaking research has led to the development of a simple DNA test to detect prostate cancer cells in blood.
Widely published in prestigious peer reviewed journals and international cancer conferences, Dr Clark is highly respected internationally in her field for her pioneering work on DNA methylation and its role in development and cancer.
|
|
|
|
|
Prof. Dr. Manfred Dietel, Charité
Manfred Dietel received his diploma in medicine (1973) and was promoted to assistant professor (1980) from the University of Hamburg. In 1983 he became full professor of anatomical and surgical pathology. Until 1989, when he became Director of the Institute of Pathology of the University of Kiel, he was member of various special research groups and was named member of the \"Medizinausschuss des Wissenschaftsrats\" of Germany in 1990. After becoming Director of the Institute of Pathology, Humboldt-University of Berlin, Charité he was named Dean of the Medical Faculty Charité, Humboldt-University of Berlin in 1997. He has been Medical Director and Head of the Board of Directors of the Charité from 1999 on and was elected President of the 2001-Congress of the European Society of Pathology. He is member of the Editorial Board of the WHO-Series "Classification of Tumours".
|
|
|
|
|
Prof. Peter A. Jones, USC Norris Cancer Center
Peter A. Jones was born in South Africa, attended school in Rhodesia (now Zimbabwe), and received his Doctor of Philosophy Degree from the University of London in 1973. He joined the University of Southern California in 1977, attaining the rank of Professor in 1985, and became Director of the Cancer Center in 1993. In 1983 he won the USC Associates Award for Creativity in Research and Scholarship. He is the author of more than 200 journal publications and book chapters, and he serves on several national and international committees, panels, and editorial boards. He has received a variety of honors, including the Outstanding Investigator Grant from the National Cancer Institute, and in 1999 was named Distinguished Professor of Biochemistry and Molecular Biology at USC. Dr Jones is known for his studies on the molecular biology of cancer and of basic mechanisms of DNA methylation and its role in cancer and differentiation.
|
|
|
|
|
Dr. Peter Laird, USC Norris Cancer Center
Peter Laird was born in Massachusetts, USA, but at the age of nine, moved to The Netherlands. He earned his BS and his MS from the University of Leiden. After receiving his PhD in 1988 at the Netherlands Cancer Institute, he joined the laboratory of Dr Anton Berns to work on gene targeting in mice. He then moved to Boston to work with Dr Rudolf Jaenisch at the Whitehead Institute. During this second postdoctoral fellowship, he used a mouse model system to provide the first direct evidence for a causal role of DNA methylation in cancer, published in the journal Cell in 1995. In 1996, he was recruited as Assistant Professor to the University of Southern California. His work at USC has led to the invention of two new DNA methylation analysis techniques, COBRA, published in 1997, and MethyLight, published in 1999, and patented in 2001.
|
|
top of the page
|
